AstraZeneca (AZN) Receives “Hold” Rating from Shore Capital

Shore Capital reissued their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Tuesday morning.

Several other equities research analysts have also issued reports on AZN. JPMorgan Chase & Co. set a GBX 5,800 ($75.79) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Monday, July 9th. Barclays reaffirmed an overweight rating and issued a GBX 6,500 ($84.93) price objective (up previously from GBX 6,300 ($82.32)) on shares of AstraZeneca in a research note on Tuesday, July 10th. Jefferies Financial Group lifted their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 6,050 ($79.05) and gave the company a buy rating in a research note on Friday, July 13th. Deutsche Bank reaffirmed a buy rating and issued a GBX 6,000 ($78.40) price objective (up previously from GBX 5,700 ($74.48)) on shares of AstraZeneca in a research note on Friday, July 13th. Finally, Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research note on Thursday, July 26th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Hold and an average price target of GBX 5,831.89 ($76.20).

Shares of LON:AZN opened at GBX 6,172 ($80.65) on Tuesday. AstraZeneca has a 12-month low of GBX 4,260 ($55.66) and a 12-month high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: What are retained earnings?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply